PARTNER PROFILE

Institute for Health Data Science, Lanzhou University | China

Accelerating the translation of evidence to practice in China.

Overview

Learn more about about the Institute for Health Data Science team and how PEERSS supports their work.

Team members

Meet the experts that make up the PEERSS team in China.

Research

See the most recent research and resources from the Institute for Health Data Science.

Connect

Connect directly with the China team.

Partner team overview

The Institute of Health Data Science at Lanzhou University was established in January 2020 and aims to accelerate the translation of evidence to practice in China.

Under the PEERSS partnership, the Institute of Health Data Science has worked to make evidence more accessible and decisions more collaborative in China.

With PEERSS funding and support, the Institute has worked to:



Disseminate social and health-related Chinese COVID-19 literature and share the Chinese experience with other countries and organizations.



Establish a COVID-19 Chinese evidence sharing platform which is accessible to researchers and decision-makers around the world.



Provide Chinese evidence and relevant policies to support other PEERSS partner teams.



Gain the trust of key decision-makers and stakeholders in the evidence-informed policymaking space.

Moving forward, partners from China will continue to promote evidence-informed policymaking by:

Xuan Yu

Role

Coordinator, Researcher

Areas of Expertise

Evidence-based social science

Country

China

Publications, policy briefs and other resources from the Institute for Health Data Science

China
Managing conflicts of interest in practice guidelines panels
Practice guidelines are an important innovation in patient care. According to the 2011 Institute of Medicine (IOM) definition, practice guidelines are “statements that include recommendations, intended to optimize patient care, that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options.”1 In the United States, guideline programs began in the early 1980s. As guidelines have been used for decisions about insurance coverage and standards for measuring quality of care, they have become increasingly influential, and conflict of interest (COI) in developing guidelines has become an important concern.
Language
English
Year Published
2017
Type of Resource
Guidelines

China
Clinical practice guidelines in China
Yaolong Chen and coworkers analyse the situation and challenges for clinical practice guidelines in China and provide recommendations for their development and implementation.
Language
English
Year Published
2018
Type of Resource
Guidelines

China
Clinical practice guidelines for COVID-19
In 2011, the United States-based Institute of Medicine (IOM) defined clinical practice guidelines as “statements that include recommendations, intended to optimize patient care, that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options”.1 In the past two decades, the number of global guidelines, whether in the field of Western medicine, traditional Chinese medicine, or integrated Chinese and Western medicine, has been growing rapidly, and its methodology has become gradually advanced.2, 3, 4, 5 Around the development, implementation, and research of the clinical practice guidelines, professional organizations (such as the Guidelines International Network, GIN6) and working groups (such as the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group,7 Appraisal of Guidelines for Research and Evaluation (AGREE) working group,8 Reporting Items for Practice Guidelines in Healthcare (RIGHT) working group9) have been established. At the same time, the guideline methodologists have naturally become a new profession.10, 11
Language
English
Year Published
2020
Type of Resource
Guidelines

China
Issue brief on Treatment for COVID-19 Pandemic
The world is now desperate to find ways to slow the spread of the novel coronavirus and to find effective treatments. To date, there are more than 200 clinical trials of COVID-19 treatments or vaccines that are either ongoing or recruiting patients. New ones are being added every day. The drugs being tested range from repurposed flu treatments to failed ebola drugs, to malaria treatments that were first developed decades ago.
Language
English
Year Published
2020
Type of Resource
Issue Brief

China
Avoidable Waste in the Production and Reporting of Evidence
The causes and degree of research waste occur in four sequential stages. But from our point of view, another very important factor we should consider is the affordability of access to published research articles. How much research is wasted because those who might benefit from it cannot afford to see its results?
Language
English
Year Published
2009
Type of Resource
EIDM Guide

Load More You’ve reached the end of the list

Have a question about the research from China?

Use the contact form below to submit a message to the PEERSS team or reach out via email.



china@peerss.org

PEERSS PARTNERS

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Institute for Health Data Science, Lanzhou University | China

Partner team overview

The Institute of Health Data Science at Lanzhou University was established in January 2020 and aims to accelerate the translation of evidence to practice in China.

Under the PEERSS partnership, the Institute of Health Data Science has worked to make evidence more accessible and decisions more collaborative in China.

With PEERSS funding and support, the Institute has worked to:

Moving forward, partners from China will continue to promote evidence-informed policymaking by:

Meet the experts from China.

Yaolong Chen

Shouyang Wu

Jingyi Zhang

Qi Wang

Xuan Yu

Issue brief on pathophysiology and clinical manifestation for COVID-19 Pandemic

Language

English

Year Published

2020

Type of Resource

Issue Brief

Managing conflicts of interest in practice guidelines panels

Language

English

Year Published

2017

Type of Resource

Guidelines

Clinical practice guidelines in China

Language

English

Year Published

2018

Type of Resource

Guidelines

Clinical practice guidelines for COVID-19

Language

English

Year Published

2020

Type of Resource

Guidelines

Issue brief on Treatment for COVID-19 Pandemic

Language

English

Year Published

2020

Type of Resource

Issue Brief

Avoidable Waste in the Production and Reporting of Evidence

Language

English

Year Published

2009

Type of Resource

EIDM Guide

Have a question about the research from China?

china@peerss.org

Explore the World of Evidence

Success!